ArticleBreast cancer research and treatment1996
Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells.
Article in Breast cancer research and treatment, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 99 citations in OpenAlex.
- Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.British journal of cancer · 1999Trial
- Resistant PRL-secreting PitNET associated with breast carcinoma: a case report and literature review.International cancer conference journal · 2025Article
- Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.Frontiers in endocrinology · 2022Review
- The SH2 domain and kinase activity of JAK2 target JAK2 to centrosome and regulate cell growth and centrosome amplification.PloS one · 2022Article
- Identification of NEK3 Kinase Threonine 165 as a Novel Regulatory Phosphorylation Site That Modulates Focal Adhesion Remodeling Necessary for Breast Cancer Cell Migration.The Journal of biological chemistry · 2016Article
- Hormone signaling requirements for the conversion of non-mammary mouse cells to mammary cell fate(s) in vivo.Journal of mammary gland biology and neoplasia · 2015Review
- Prolactin and prolactin receptor expression in cervical intraepithelial neoplasia and cancer.Pathology oncology research : POR · 2015Article
- Tyrosyl phosphorylated serine-threonine kinase PAK1 is a novel regulator of prolactin-dependent breast cancer cell motility and invasion.Advances in experimental medicine and biology · 2015Review
- Tyrosyl phosphorylated PAK1 regulates breast cancer cell motility in response to prolactin through filamin A.Molecular endocrinology (Baltimore, Md.) · 2013Article
- Characterization of Δ7/11, a functional prolactin-binding protein.Journal of molecular endocrinology · 2013Article
- Life stage differences in mammary gland gene expression profile in non-human primates.Breast cancer research and treatment · 2012Article
- Increased expression of the prolactin receptor is associated with malignant laryngeal tumors.Experimental and therapeutic medicine · 2012Article
- Adapter protein SH2B1beta binds filamin A to regulate prolactin-dependent cytoskeletal reorganization and cell motility.Molecular endocrinology (Baltimore, Md.) · 2011Article
- Prolactin-mediated regulation of lipid biosynthesis genes in vivo in the lactating mammary epithelial cell.American journal of physiology. Endocrinology and metabolism · 2011Article
- Synergy in ERK activation by cytokine receptors and tyrosine kinase growth factor receptors.Cellular signalling · 2011Article
- Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism.Cancer research · 2010Article
- Prolactin activates mitogen-activated protein kinase signaling and corticotropin releasing hormone transcription in rat hypothalamic neurons.Endocrinology · 2009Article
- Regulation of prolactin receptor levels and activity in breast cancer.Journal of mammary gland biology and neoplasia · 2008Review
- Prolactin regulation of mammary gland development.Journal of mammary gland biology and neoplasia · 2008Review
- Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.Oncogene · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The polypeptide hormone prolactin (Prl), acting through its cell surface receptors, promotes growth and differentiation in normal and malignant breast cells. We demonstrate herein that two Prl-responsive cell lines, NOG-8 normal mouse mammary epithelial and T47D human breast cancer cells, respond to Prl by rapid and transient activation of a series of kinases. Raf-1 was activated within 2-5 min of Prl treatment. This was followed rapidly by activation of MEK (MAP kinase kinase) and MAP kinase activity in these cells. Increased MAP kinase activity was accompanied by tyrosine phosphorylation of both the 42 kDa and 44 kDa isoforms. The tyrosine kinase inhibitors genestein and tyrphostin blocked the increase in MAP kinase activity as well as Prl induced growth of the T47D cells. These results indicate that the Prl receptor, after binding to Prl in mammary cells, activates the raf-MEK-MAP kinase pathway for signal transduction leading to mitogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.